Please note that the copy function is not enabled for this field.
If you wish to
modify
existing outcomes, please copy and paste the current outcome text into the Update field.
LOGIN
CREATE ACCOUNT
LOGIN
CREATE ACCOUNT
MY TRIALS
REGISTER TRIAL
FAQs
HINTS AND TIPS
DEFINITIONS
Trial Review
The ANZCTR website will be unavailable from 1pm until 3pm (AEDT) on Wednesday the 30th of October for website maintenance. Please be sure to log out of the system in order to avoid any loss of data.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this
information for consumers
Download to PDF
Trial details imported from ClinicalTrials.gov
For full trial details, please see the original record at
https://clinicaltrials.gov/study/NCT01676116
Registration number
NCT01676116
Ethics application status
Date submitted
28/08/2012
Date registered
30/08/2012
Date last updated
3/01/2019
Titles & IDs
Public title
The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy
Query!
Scientific title
The Efficacy of Insulin Degludec/Liraglutide in Controlling Glycaemia in Adults With Type 2 Diabetes Inadequately Controlled on GLP-1 Receptor Agonist and OAD Therapy (DUAL™ III -GLP-1 Switch)
Query!
Secondary ID [1]
0
0
2012-000209-63
Query!
Secondary ID [2]
0
0
NN9068-3851
Query!
Universal Trial Number (UTN)
Query!
Trial acronym
DUAL™ III
Query!
Linked study record
Query!
Health condition
Health condition(s) or problem(s) studied:
Diabetes
0
0
Query!
Diabetes Mellitus, Type 2
0
0
Query!
Condition category
Condition code
Metabolic and Endocrine
0
0
0
0
Query!
Diabetes
Query!
Intervention/exposure
Study type
Interventional
Query!
Description of intervention(s) / exposure
Treatment: Drugs - insulin degludec/liraglutide
Treatment: Drugs - liraglutide
Treatment: Drugs - exenatide
Experimental: Insulin degludec/liraglutide + OADs -
Active comparator: Liraglutide or exenatide + OADs -
Treatment: Drugs: insulin degludec/liraglutide
Injected subcutaneously (under the skin) once daily. Dose individually adjusted. Subjects will continue their pre-trial OAD treatment without changing the frequency or dose throughout the trial.
Treatment: Drugs: liraglutide
Subjects will continue on their pre-trial treatment of liraglutide (Victoza®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.
Treatment: Drugs: exenatide
Subjects will continue on their pre-trial treatment of exenatide (Byetta®) (GLP-1 receptor agonist) + OAD without changing the frequency or dose throughout the trial.
Query!
Intervention code [1]
0
0
Treatment: Drugs
Query!
Comparator / control treatment
Query!
Control group
Query!
Outcomes
Primary outcome [1]
0
0
Change in Glycosylated Haemoglobin (HbA1c) From Baseline (Randomisation, Visit 2)
Query!
Assessment method [1]
0
0
Query!
Timepoint [1]
0
0
Week 0, week 26
Query!
Secondary outcome [1]
0
0
Responders Achieving Pre-defined Target: HbA1c Below 7.0% (53 mmol/Mol)
Query!
Assessment method [1]
0
0
Percentage of subjects achieving HbA1c below 7.0% after 26 weeks of treatment.
Query!
Timepoint [1]
0
0
Week 26
Query!
Secondary outcome [2]
0
0
Responders Achieving Pre-defined Target: HbA1c Below or Equal to 6.5% (48 mmol/Mol)
Query!
Assessment method [2]
0
0
Percentage of responders achieving pre-defined target for HbA1c - HbA1c = 6.5% (48 mmol/mol).
Query!
Timepoint [2]
0
0
Week 26
Query!
Secondary outcome [3]
0
0
Change From Baseline in Body Weight
Query!
Assessment method [3]
0
0
Mean change in body weight after 26 weeks of treatment.
Query!
Timepoint [3]
0
0
Week 0, week 26
Query!
Secondary outcome [4]
0
0
Change From Baseline in Fasting Plasma Glucose (FPG)
Query!
Assessment method [4]
0
0
Mean change in fasting plasma glucose from baseline, after 26 weeks of treatment.
Query!
Timepoint [4]
0
0
Week 0, week 26
Query!
Secondary outcome [5]
0
0
Number of Severe or Minor Hypoglycaemic Episodes
Query!
Assessment method [5]
0
0
Rate (events per 100 patient years of exposure) of treatment-emergent confirmed hypoglycaemic episodes. The pool of severe and minor hypoglycaemic episodes was referred to as confirmed hypoglycaemic episodes. Severe hypoglycaemia was categorised as an episode requiring assistance of another person to actively administer carbohydrate, glucagon, or other resuscitative actions. Minor hypoglycaemic episodes were defined as an episode with symptoms consistent with hypoglycaemia with confirmation by blood glucose \<2.8 mmol/L (50 mg/dL) or PG \<3.1 mmol/L (56 mg/dL), and which was handled by the subject himself/herself, or any asymptomatic blood glucose value \<2.8 mmol/L (50 mg/dL) or PG value \<3.1 mmol/L (56 mg/dL).
Query!
Timepoint [5]
0
0
After 26 weeks of treatment
Query!
Secondary outcome [6]
0
0
Number of Adverse Events (AEs)
Query!
Assessment method [6]
0
0
Rate (events per 100 exposure years) of treatment-emergent adverse events (an event that had onset date (or an increase in severity) on or after the first day of exposure to randomised treatment and no later than 7 days after the last day of randomised treatment) which occurred during the 26 weeks of treatment.
Query!
Timepoint [6]
0
0
After 26 weeks of treatment
Query!
Secondary outcome [7]
0
0
Change From Baseline in Patient Reported Outcomes (PROs) Based on the Treatment Related Impact Measure - Diabetes (TRIM-D)
Query!
Assessment method [7]
0
0
The patient related outcome is calculated based on TRIM-D questionnaire. The TRIM-D questionnaire consists of 5 sub-domains (treatment burden, daily life, diabetes management, compliance and psychological health), where each question is scored to a 1-5-point scale with a higher score indicating a better health state (less negative impact). Mean TRIM-D individual sub-domain scores and total score are later transformed to a 0-100 scale for analysis. The mean change in scores from baseline to 26 weeks for all the individual sub domains and total scores are presented here.
Query!
Timepoint [7]
0
0
Week 0, week 26
Query!
Secondary outcome [8]
0
0
Change From Baseline in Patient Reported Outcomes (PROs) Based on Diabetes Treatment Satisfaction Questionnaire (DTSQ).
Query!
Assessment method [8]
0
0
Mean change in diabetes treatment satisfaction questionnaire (DTSQs) scores from baseline. The scores ranged from 0 to 6. Higher total score on a 0-6 point scale indicates a general higher treatment satisfaction, whereas higher score on perceived frequency of hyperglycaemia and perceived frequency of hypoglycaemia indicate that blood glucose levels are out of the target range.
Query!
Timepoint [8]
0
0
Week 0, week 26
Query!
Eligibility
Key inclusion criteria
* Subjects with type 2 diabetes mellitus
* Glycosylated haemoglobin (HbA1c) 7.0-9.0% (53-75 mmol/mol) (both inclusive)
* Treatment with daily GLP-1 receptor agonist at maximum dose according to local label (i.e. 1.8 mg once daily (OD) Victoza® (liraglutide) or 10 microgram twice daily (BID) Byetta® (exenatide)) or documented maximum tolerated dose (i.e. 1.2 mg OD Victoza® (liraglutide) or 5 microgram BID Byetta® (exenatide)) in combination with a stable daily dose of metformin (equal to or above 1500 mg or documented maximum tolerated dose) for 90 days or more prior to screening visit (Visit 1)
* BMI (body mass index) equal to or below 40 kg/m^2
Query!
Minimum age
18
Years
Query!
Query!
Maximum age
No limit
Query!
Query!
Sex
Both males and females
Query!
Can healthy volunteers participate?
No
Query!
Key exclusion criteria
* Any use of oral anti-diabetic drugs (OADs) (except for metformin, pioglitazone and sulphonylurea) for 90 days or less prior to screening visit (Visit 1)
* Use of any drug (except metformin,pioglitazone, sulphonylurea and GLP-1 receptor agonist) which in the Investigator's opinion could interfere with the blood glucose level (e.g. systemic corticosteroids)
* Treatment with any insulin regimen (short term treatment due to intercurrent illness including gestational diabetes is allowed at the discretion of the Investigator)
* Screening calcitonin equal to or above 50 ng/l
* Personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN2)
* Cardiovascular disorders defined as: congestive heart failure (New York Heart Association (NYHA) class III-IV), diagnosis of unstable angina pectoris, cerebral stroke and/or myocardial infarction within the past 52 weeks prior to screening visit (Visit 1) and/or planned coronary, carotid or peripheral artery revascularisation procedures
* Proliferative retinopathy requiring acute treatment or maculopathy (macular oedema) according to the Investigator's opinion
* Subjects with a clinically significant, active (during the past 12 months) disease of the gastrointestinal, pulmonary, endocrinological (except for the type 2 diabetes mellitus), neurological, genitourinary or haematological system that in the opinion of the Investigator may confound the results of the trial or pose additional risk in administering trial products
* History of chronic pancreatitis or idiopathic acute pancreatitis
Query!
Study design
Purpose of the study
Treatment
Query!
Allocation to intervention
Randomised controlled trial
Query!
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Query!
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Query!
Masking / blinding
Open (masking not used)
Query!
Who is / are masked / blinded?
Query!
Query!
Query!
Query!
Intervention assignment
Parallel
Query!
Other design features
Query!
Phase
Phase 3
Query!
Type of endpoint/s
Query!
Statistical methods / analysis
Query!
Recruitment
Recruitment status
Completed
Query!
Data analysis
Query!
Reason for early stopping/withdrawal
Query!
Other reasons
Query!
Date of first participant enrolment
Anticipated
Query!
Actual
29/08/2012
Query!
Date of last participant enrolment
Anticipated
Query!
Actual
Query!
Date of last data collection
Anticipated
Query!
Actual
11/03/2014
Query!
Sample size
Target
Query!
Accrual to date
Query!
Final
438
Query!
Recruitment in Australia
Recruitment state(s)
NSW,SA,VIC
Query!
Recruitment hospital [1]
0
0
Novo Nordisk Investigational Site - Coffs Harbour
Query!
Recruitment hospital [2]
0
0
Novo Nordisk Investigational Site - Merewether
Query!
Recruitment hospital [3]
0
0
Novo Nordisk Investigational Site - Keswick
Query!
Recruitment hospital [4]
0
0
Novo Nordisk Investigational Site - Box Hill
Query!
Recruitment hospital [5]
0
0
Novo Nordisk Investigational Site - Melbourne
Query!
Recruitment postcode(s) [1]
0
0
2450 - Coffs Harbour
Query!
Recruitment postcode(s) [2]
0
0
2291 - Merewether
Query!
Recruitment postcode(s) [3]
0
0
5035 - Keswick
Query!
Recruitment postcode(s) [4]
0
0
3128 - Box Hill
Query!
Recruitment postcode(s) [5]
0
0
3004 - Melbourne
Query!
Recruitment outside Australia
Country [1]
0
0
United States of America
Query!
State/province [1]
0
0
Alabama
Query!
Country [2]
0
0
United States of America
Query!
State/province [2]
0
0
Arizona
Query!
Country [3]
0
0
United States of America
Query!
State/province [3]
0
0
California
Query!
Country [4]
0
0
United States of America
Query!
State/province [4]
0
0
Colorado
Query!
Country [5]
0
0
United States of America
Query!
State/province [5]
0
0
Florida
Query!
Country [6]
0
0
United States of America
Query!
State/province [6]
0
0
Georgia
Query!
Country [7]
0
0
United States of America
Query!
State/province [7]
0
0
Hawaii
Query!
Country [8]
0
0
United States of America
Query!
State/province [8]
0
0
Illinois
Query!
Country [9]
0
0
United States of America
Query!
State/province [9]
0
0
Indiana
Query!
Country [10]
0
0
United States of America
Query!
State/province [10]
0
0
Kentucky
Query!
Country [11]
0
0
United States of America
Query!
State/province [11]
0
0
Maryland
Query!
Country [12]
0
0
United States of America
Query!
State/province [12]
0
0
Michigan
Query!
Country [13]
0
0
United States of America
Query!
State/province [13]
0
0
Missouri
Query!
Country [14]
0
0
United States of America
Query!
State/province [14]
0
0
Nebraska
Query!
Country [15]
0
0
United States of America
Query!
State/province [15]
0
0
Nevada
Query!
Country [16]
0
0
United States of America
Query!
State/province [16]
0
0
New Hampshire
Query!
Country [17]
0
0
United States of America
Query!
State/province [17]
0
0
New Jersey
Query!
Country [18]
0
0
United States of America
Query!
State/province [18]
0
0
New York
Query!
Country [19]
0
0
United States of America
Query!
State/province [19]
0
0
North Carolina
Query!
Country [20]
0
0
United States of America
Query!
State/province [20]
0
0
Ohio
Query!
Country [21]
0
0
United States of America
Query!
State/province [21]
0
0
Pennsylvania
Query!
Country [22]
0
0
United States of America
Query!
State/province [22]
0
0
South Carolina
Query!
Country [23]
0
0
United States of America
Query!
State/province [23]
0
0
Tennessee
Query!
Country [24]
0
0
United States of America
Query!
State/province [24]
0
0
Texas
Query!
Country [25]
0
0
United States of America
Query!
State/province [25]
0
0
Utah
Query!
Country [26]
0
0
United States of America
Query!
State/province [26]
0
0
Virginia
Query!
Country [27]
0
0
France
Query!
State/province [27]
0
0
Antibes
Query!
Country [28]
0
0
France
Query!
State/province [28]
0
0
Boulogne Billancourt
Query!
Country [29]
0
0
France
Query!
State/province [29]
0
0
LA ROCHELLE cedex
Query!
Country [30]
0
0
France
Query!
State/province [30]
0
0
Montigny-les-Metz
Query!
Country [31]
0
0
France
Query!
State/province [31]
0
0
Narbonne
Query!
Country [32]
0
0
France
Query!
State/province [32]
0
0
Nimes
Query!
Country [33]
0
0
France
Query!
State/province [33]
0
0
Sète
Query!
Country [34]
0
0
France
Query!
State/province [34]
0
0
Venissieux
Query!
Country [35]
0
0
Hungary
Query!
State/province [35]
0
0
Budapest
Query!
Country [36]
0
0
Hungary
Query!
State/province [36]
0
0
Debrecen
Query!
Country [37]
0
0
Hungary
Query!
State/province [37]
0
0
Nyíregyhaza
Query!
Country [38]
0
0
Hungary
Query!
State/province [38]
0
0
Székesfehérvár
Query!
Country [39]
0
0
Slovakia
Query!
State/province [39]
0
0
Bratislava
Query!
Country [40]
0
0
Slovakia
Query!
State/province [40]
0
0
Kosice
Query!
Country [41]
0
0
Slovakia
Query!
State/province [41]
0
0
Lucenec
Query!
Country [42]
0
0
Slovakia
Query!
State/province [42]
0
0
Nitra
Query!
Country [43]
0
0
Slovakia
Query!
State/province [43]
0
0
Presov
Query!
Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Query!
Name
Novo Nordisk A/S
Query!
Address
Query!
Country
Query!
Ethics approval
Ethics application status
Query!
Summary
Brief summary
This trial is conducted in Europe, Oceania and the United States of America (USA). The aim of the trial is to investigate the efficacy of insulin degludec/liraglutide in controlling glycaemia in adults with type 2 diabetes inadequately controlled on glucagon-like peptide-1 (GLP-1) receptor agonist and OAD therapy.
Query!
Trial website
https://clinicaltrials.gov/study/NCT01676116
Query!
Trial related presentations / publications
Linjawi S, Bode BW, Chaykin LB, Courreges JP, Handelsman Y, Lehmann LM, Mishra A, Simpson RW. The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial. Diabetes Ther. 2017 Feb;8(1):101-114. doi: 10.1007/s13300-016-0218-3. Epub 2016 Dec 10. Lingvay I, Handelsman Y, Linjawi S, Vilsboll T, Halladin N, Ranc K, Liebl A. EFFICACY AND SAFETY OF IDEGLIRA IN OLDER PATIENTS WITH TYPE 2 DIABETES. Endocr Pract. 2019 Feb;25(2):144-155. doi: 10.4158/EP-2018-0284. Epub 2018 Nov 1.
Query!
Public notes
Query!
Contacts
Principal investigator
Name
0
0
Global Clinical Registry (GCR, 1452)
Query!
Address
0
0
Novo Nordisk A/S
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for public queries
Name
0
0
Query!
Address
0
0
Query!
Country
0
0
Query!
Phone
0
0
Query!
Fax
0
0
Query!
Email
0
0
Query!
Contact person for scientific queries
No information has been provided regarding IPD availability
What supporting documents are/will be available?
No Supporting Document Provided
Results publications and other study-related documents
Type
Citations or Other Details
Journal
Linjawi S, Bode BW, Chaykin LB, Courreges JP, Hand...
[
More Details
]
Journal
Lingvay I, Handelsman Y, Linjawi S, Vilsboll T, Ha...
[
More Details
]
Results are available at
https://clinicaltrials.gov/study/NCT01676116
Download to PDF